In March 2024, Blackstone Life Sciences committed up to $750 million to fund Moderna's mRNA-based influenza vaccine program, including its lead candidate mRNA-1010. In exchange, the private equity giant secured rights to commercial milestone payments and low-single-digit royalties on resulting products. This deal was positioned as support for innovative mRNA technology at a time when Moderna faced declining COVID-19 vaccine revenues.[1][2]

Fast forward to February 2026: Under the post-Marks leadership at the FDA's Center for Biologics Evaluation and Research (CBER), the agency issued a rare "refusal to file" letter rejecting Moderna's biologics license application for mRNA-1010. The cited reason was that the Phase 3 trial's comparator arm did not use what regulators deemed the "best available" high-dose flu vaccine for older adults, despite prior FDA communications that had not flagged this as disqualifying. The decision, associated with new vaccine leadership installed after significant turnover, sparked immediate industry criticism and questions about shifting standards.[3][4]

Just one week later, the FDA reversed course. After Moderna agreed to additional studies in older populations, the agency accepted the application with a target review completion by August 2026. This swift about-face occurred amid public backlash and broader tensions at HHS following the 2025 resignation of longtime CBER Director Dr. Peter Marks, who cited clashes with HHS Secretary Robert F. Kennedy Jr. over vaccine policy and what Marks described as promotion of misinformation. Marks' departure was part of larger post-COVID realignments that amplified distrust in regulatory processes.[5][6][7]

While mainstream reporting contains no smoking-gun evidence of direct Blackstone pressure on the FDA, the timeline overlap is striking: a massive private-equity infusion into Moderna's flu program precedes regulatory turbulence under an administration skeptical of certain mRNA applications. This episode exemplifies deeper structural issues of regulatory capture, where alternative asset managers like Blackstone—managing vast healthcare portfolios—hold indirect sway over innovation pipelines and, by extension, public health policy. It mirrors persistent post-COVID patterns: eroded trust in mRNA platforms, politicization of vaccine oversight, and questions about whether financial stakeholders benefit from accelerated or selectively enforced approvals.

Connections often missed include the broader shift from traditional pharma funding to private equity dominance. Blackstone's investment de-risks Moderna's program while tying returns to regulatory success and commercialization. In an environment where FDA leadership changes (Marks out in 2025, followed by figures like Vinay Prasad shaping 2026 decisions before later transitions) coincide with these financial stakes, the independence of "public" health gatekeepers appears strained. This dynamic risks further polarizing vaccine acceptance, as observers note that perceived conflicts—whether real or optics-driven—reinforce narratives of captured institutions prioritizing investor returns over rigorous, transparent science.